Premium
Endothelial biomarkers as indicators of cardiovascular complications in young patients with arterial hypertension
Author(s) -
Lyamidezhda P.,
Lyamina Svetlana V.,
Downey H. Fred,
Manukhina Eugenia B.
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.872.20
Subject(s) - medicine , reactive hyperemia , brachial artery , blood pressure , cardiology , nitric oxide , endothelial dysfunction , vasodilation , endothelin 1 , endothelin receptor , arterial stiffness , endocrinology , receptor
This study evaluated nitric oxide (NO) and endothelin‐1 (ET‐1) as clinically relevant biomarkers in young patients with early arterial hypertension (AH). Male patients (n=65, 20–45 years of age) with AH duration <6 years and blood pressure (BP) <160/100 mm Hg were studied. A control group consisted of 32 age‐matched healthy subjects. Endothelium‐dependent vasodilation (EDVD) was evaluated by measuring post‐occlusion reactive hyperemia in the brachial artery. NO production was evaluated by plasma concentration and 24‐hour urinary excretion of nitrite + nitrate. Plasma concentration of ET‐1 was measured by immunoenzyme assay. The plasma NO/ET‐1 ratio was calculated. EDVD was 12.3% lower in patients with AH than in healthy subjects, and this decrease correlated with the duration of AH. The NO/ET‐1 ratio was significantly lower in the AH group (2.0±0.4 vs 6.2±0.6, p<0.001), and the NO/ET‐1 ratio decreased with AH duration. NO/ET‐1 values below 3.0 were associated with atypical diurnal BP profile and cardiac arrhythmias. NO/ET‐1 values below 1.0 were associated with severe cardiovascular complications. Thus, the ratio of NO to ET‐1 appears to be a useful marker for cardiovascular complications in young patients with arterial hypertension.